NCT02435654View on ClinicalTrials.gov

5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia

PHASE4CompletedINTERVENTIONAL

Enrollment

128

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Early-onset Schizophrenia

Interventions

DRUG

olanzapine

olanzapine will be initiated at 2.5 or 5 mg/day according to patient's weight, and the dose could be increased by 2.5 or 5 mg every 4-7days at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,

Trial Locations (1)

650032

Psychiatry Department,First Affiliated Hospial Of Kunming Medical University, Kunming

All Listed Sponsors

collaborator

National Natural Science Foundation of China

OTHER_GOV

lead

Kunming Medical University

OTHER

NCT02435654 - 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia | Biotech Hunter | Biotech Hunter